切换至 "中华医学电子期刊资源库"

中华诊断学电子杂志 ›› 2022, Vol. 10 ›› Issue (04) : 248 -252. doi: 10.3877/cma.j.issn.2095-655X.2022.04.007

心血管疾病诊治

酒精性心肌病病理分子机制的研究进展
路旗1, 李传方2, 甘立军2,()   
  1. 1. 272013 济宁医学院临床医学院
    2. 272029 济宁医学院附属医院心血管内科
  • 收稿日期:2022-01-16 出版日期:2022-11-25
  • 通信作者: 甘立军
  • 基金资助:
    济宁市重点研发计划项目(2020JKNS006); 济宁医学院国家自然科学基金培育项目(JYP2019KJ31)

Advances in molecular mechanisms of alcoholic cardiomyopathy

Qi Lu1, Chuanfang Li2, Lijun Gan2,()   

  1. 1. College of Clinical Medicine, Jining Medical University, Jining 272013, China
    2. Department of Cardiovascular Medicine, the Affiliated Hospital of Jining Medical University, Jining 272029, China
  • Received:2022-01-16 Published:2022-11-25
  • Corresponding author: Lijun Gan
引用本文:

路旗, 李传方, 甘立军. 酒精性心肌病病理分子机制的研究进展[J/OL]. 中华诊断学电子杂志, 2022, 10(04): 248-252.

Qi Lu, Chuanfang Li, Lijun Gan. Advances in molecular mechanisms of alcoholic cardiomyopathy[J/OL]. Chinese Journal of Diagnostics(Electronic Edition), 2022, 10(04): 248-252.

酒精性心肌病(ACM)是一种由于长期大量饮酒所引发的非缺血性扩张型心肌病,发病率逐年增高。ACM的发病机制涉及酒精及其代谢产物的直接毒性作用、氧化应激、细胞凋亡与自噬、线粒体功能障碍、蛋白质代谢异常和神经内分泌系统失衡等多方面,且尚未明确,临床表现及诊断也缺乏特异性。笔者主要对ACM的发病机制、病理特征、临床特征、诊断与治疗等方面的研究进展进行综述,以提高医务工作者对其的认识。

Alcoholic cardiomyopathy (ACM), a type of non-ischemic dilated cardiomyopathy whose morbidity is rising year by year, is brought on by heavy drinking. With clinical manifestations and diagnosis lacking specificity, the pathogenesis of ACM includes the direct toxic effects of alcohol and its metabolites, oxidative stress, apoptosis and autophagy, mitochondrial dysfunction, abnormal protein metabolism, neuroendocrine system imbalance, and other unknown factors. This article mainly reviews the research progress in the pathogenesis, pathological features, clinical features, diagnosis and treatment of ACM, so as to improve the understanding of medical professionals.

[1]
王昭,吴其明.酒精性心肌病临床特点及治疗研究进展[J/CD].中国医学前沿杂志(电子版)201911(6):7-11.DOI:10.12037/YXQY.2019.06-02.
[2]
Li X, Nie Y, Lian H, et al. Histopathologic features of alcoholic cardiomyopathy compared with idiopathic dilated cardiomyopathy[J].Medicine (Baltimore)201897(39):e12259.DOI:10.1097/MD.0000000000012259.
[3]
Mogos MF, Salemi JL, Phillips SA,et al.Contemporary appraisal of sex differences in prevalence,correlates,and outcomes of alcoholic cardiomyopathy[J].Alcohol Alcohol201954(4):386-395.DOI:10.1093/alcalc/agz050.
[4]
Fernández-Solà J. The effects of ethanol on the heart: alcoholic cardiomyopathy[J].Nutrients202012(2):572.DOI:10.3390/nu12020572.
[5]
Rehm J, Hasan OSM, Imtiaz S,et al.Quantifying the contribution of alcohol to cardiomyopathy:a systematic review[J].Alcohol2017(61):9-15.DOI:10.1016/j.alcohol.2017.01.011.
[6]
范晓飞,张清,刘贵京.乙醇性心肌病的研究进展[J].心血管病学进展201637(4):379-383.DOI:10.16806/j.cnki.issn.1004-3934.2016.04.014.
[7]
Klatsky AL.Alcohol and cardiovascular diseases:where do we stand today? [J].J Intern Med2015278(3):238-250.DOI:10.1111/joim.12390.
[8]
Leibing E, Meyer T.Enzymes and signal pathways in the pathogenesis of alcoholic cardiomyopathy [J].Herz201641(6):478-483.DOI:10.1007/s00059-016-4459-8.
[9]
Guo R, Ren J.Alcohol dehydrogenase accentuates ethanol-induced myocardial dysfunction and mitochondrial damage in mice:role of mitochondrial death pathway[J].PLoS One20105(1):e8757.DOI:10.1371/journal.pone.0008757.
[10]
Day E, Rudd JHF.Alcohol use disorders and the heart[J].Addiction2019114(9):1670-1678.DOI:10.1111/add.14703.
[11]
Piano MR, Phillips SA.Alcoholic cardiomyopathy:pathophysiologic insights[J].Cardiovasc Toxicol201414(4):291-308.DOI:10.1007/s12012-014-9252-4.
[12]
Harjumäki R, Pridgeon CS, Ingelman-Sundberg M. CYP2E1 in alcoholic and non-alcoholic liver injury.Roles of ROS,reactive intermediates and lipid overload[J].Int J Mol Sci202122(15):8221.DOI:10.3390/ijms22158221.
[13]
Tu X, Wang C, Ru X, et al. Therapeutic effects of rapamycin on alcoholic cardiomyopathy[J].Exp Ther Med201714(4):2763-2770.DOI:10.3892/etm.2017.4901.
[14]
Steiner JL, Lang CH.Alcoholic cardiomyopathy:disrupted protein balance and impaired cardiomyocyte contractility[J].Alcohol Clin Exp Res201741(8):1392-1401.DOI:10.1111/acer.13405.
[15]
Wang S, Ren J. Role of autophagy and regulatory mechanisms in alcoholic cardiomyopathy[J].Biochim Biophys Acta Mol Basis Dis20181864(6 Pt A):2003-2009.DOI:10.1016/j.bbadis.2018.03.016.
[16]
Zhu Z, Huang Y, Lv L,et al.Acute ethanol exposure-induced autophagy-mediated cardiac injury via activation of the ROS-JNK-Bcl-2 pathway[J].J Cell Physiol2018233(2):924-935.DOI:10.1002/jcp.25934.
[17]
高学忠,黄隐青,林丛,等.PTEN介导的自噬对慢性酒精刺激引起的心肌损害的保护作用[J].心脑血管病防治201818(2):102-107.DOI:10.3969/j.issn.1009-816x.2018.02.005.
[18]
Prasun P, Ginevic I, Oishi K.Mitochondrial dysfunction in nonalcoholic fatty liver disease and alcohol related liver disease[J].Transl Gastroenterol Hepatol2021(6):4.DOI:10.21037/tgh-20-125.
[19]
于静,吴晓羽.线粒体自噬与心血管疾病[J].中国循证心血管医学杂志20179(4):500-501,506.DOI:10.3969/j.issn.1674-4055.2017.04.36.
[20]
Yang M, Wang S, Fu S,et al.Deletion of the E3 ubiquitin ligase,parkin,exacerbates chronic alcohol intake-induced cardiomyopathy through an ambra1-dependent mechanism[J].Br J Pharmacol2021178(4):964-982.DOI:10.1111/bph.15340.
[21]
Piano MR.Alcohol's effects on the cardiovascular system[J].Alcohol Res Curr Rev201738(2) :219-241.
[22]
Baar EL, Carbajal KA, Ong IM,et al.Sex- and tissue-specific changes in mTOR signaling with age in C57BL/6J mice[J].Aging Cell201615(1):155-166.DOI:10.1111/acel.12425.
[23]
Brandt M, Wenzel P.Alcohol puts the heart under pressure:acetaldehyde activates a localized renin angiotensin aldosterone system within the myocardium in alcoholic cardiomyopathy[J].Int J Cardiol2018(257):220-221.DOI:10.1016/j.ijcard.2018.01.037.
[24]
胡军,于波.酒精性心肌病发病机制研究新进展[J].中国循证心血管医学杂志20146(2):236-238.DOI:10.3969/j.1674-4055.2014.02.38.
[25]
Cheng CP, Cheng HJ, Cunningham C,et al.Angiotensin Ⅱ type 1 receptor blockade prevents alcoholic cardiomyopathy[J].Circulation2006114(3):226-36.DOI:10.1161/CIRCULATIONAHA.105.596494.
[26]
Lin L, Liu X, Xu J,et al.Mas receptor mediates cardioprotection of angiotensin-(1-7) against angiotensin II-induced cardiomyocyte autophagy and cardiac remodelling through inhibition of oxidative stress[J].J Cell Mol Med201620(1):48-57.DOI:10.1111/jcmm.12687.
[27]
Xiong J, Cao X, Qiao S,et al.(Pro)renin receptor is involved in myocardial damage in alcoholic cardiomyopathy[J].Alcohol Clin Exp Res201943(11):2344-2353.DOI:10.1111/acer.14188.
[28]
Fernández-Solà J, Nicolás JM, Oriola J,et al.Angiotensin-converting enzyme gene polymorphism is associated with vulnerability to alcoholic cardiomyopathy[J].Ann Intern Med2002137(5 Part 1):321-326.DOI:10.7326/0003-4819-137-5_part_1-200209030-00007.
[29]
Liu B, Zhang R, Wei S, et al. ALDH2 protects against alcoholic cardiomyopathy through a mechanism involving the p38 MAPK/CREB pathway and local renin-angiotensin system inhibition in cardiomyocytes[J].Int J Cardiol2018(257):150-159.DOI:10.1016/j.ijcard.2017.11.094.
[30]
Ma H, Yu L, Byra EA,et al.Aldehyde dehydrogenase 2 knockout accentuates ethanol-induced cardiac depression:role of protein phosphatases[J].J Mol Cell Cardiol201049(2):322-329.DOI:10.1016/j.yjmcc.2010.03.017.
[31]
Piano MR.Alcoholic cardiomyopathy:incidence,clinical characteristics,and pathophysiology[J].Chest2002121(5):1638-1650.DOI:10.1378/chest.121.5.1638.
[32]
Guzzo-Merello G, Cobo-Marcos M, Gallego-Delgado M,et al.Alcoholic cardiomyopathy[J].World J Cardiol20146(8):771-781.DOI:10.4330/wjc.v6.i8.771.
[33]
Fernández-Solà J.Cardiovascular risks and benefits of moderate and heavy alcohol consumption[J].Nat Rev Cardiol201512(10):576-587.DOI:10.1038/nrcardio.2015.91.
[34]
Hung CL, Gonçalves A, Lai YJ,et al.Light to moderate habitual alcohol con-sumption is associated with subclinical ventricular and left atrial mechanical dys-function in an asymptomatic population:dose-response and propensity analysis[J].J Am Soc Echocardiogr201629(11):1043-1051.DOI:10.1016/j.echo.2016.07.014.
[35]
Maisch B.Alcoholic cardiomyopathy:the result of dosage and individual predisposition[J].Herz201641(6):484-493.DOI:10.1007/s00059-016-4469-6.
[36]
O'Keefe EL, DiNicolantonio JJ, O'Keefe JH,et al.Alcohol and CV Health:Jekyll and Hyde J-Curves[J].Prog Cardiovasc Dis201861(1):68-75.DOI:10.1016/j.pcad.2018.02.001.
[37]
Elliott P, Andersson B, Arbustini E, et al. Classification of the cardiomyopathies:a position statement from the european society of cardiology working group on myocardial and pericardial diseases[J].Eur Heart J200829(2):270-276.DOI:10.1093/eurheartj/ehm342.
[38]
葛均波,徐永健,王辰.内科学[M].9版.北京:人民卫生出版社,2018:265.
[39]
Addolorato G, Mirijello A, Barrio P,et al.Treatment of alcohol use disorders in patients with alcoholic liver disease[J].J Hepatol201665(3):618-630.DOI:10.1016/j.jhep.2016.04.029.
[40]
Ponikowski P, Voors AA, Anker SD,et al.2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure:the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC).Developed with the special contribution of the Heart Failure Association (HFA) of the ESC[J].Eur J Heart Fail201618(8):891-975.DOI:10.1002/ejhf.592.
[41]
Guzzo-Merello G, Dominguez F, González-López E,et al.Malignant ventricular arrhythmias in alcoholic cardiomyopathy[J].Int J Cardiol2015(199):99-105.DOI:10.1016/j.ijcard.2015.07.029.
[42]
Ferrer-Curriu G, Guitart-Mampel M, Rupérez C,et al.The protective effect of fibroblast growth factor-21 in alcoholic cardiomyopathy:a role in protecting cardiac mitochondrial function[J].J Pathol2021253(2):198-208.DOI:10.1002/path.5573.
[43]
Guzzo-Merello G, Segovia J, Dominguez F,et al.Natural history and prognostic factors in alcoholic cardiomyopathy[J].JACC Heart Fail20153(1):78-86.DOI:10.1016/j.jchf.2014.07.014.
[44]
Fang W, Luo R, Tang Y,et al.The prognostic factors of alcoholic cardiomyopathy:a single-center cohort study[J].Medicine (Baltimore)201897(31):e11744.DOI:10.1097/MD.0000000000011744.
[45]
Dundung A, Kumar A, Guria RT, et al. Clinical profile and prognostic factors of alcoholic cardiomyopathy in tribal and non-tribal population[J].Open Heart20207(2):e001335.DOI:10.1136/openhrt-2020-001335.
[1] 王亚红, 蔡胜, 葛志通, 杨筱, 李建初. 颅骨骨膜窦的超声表现一例[J/OL]. 中华医学超声杂志(电子版), 2024, 21(11): 1089-1091.
[2] 史学兵, 谢迎东, 谢霓, 徐超丽, 杨斌, 孙帼. 声辐射力弹性成像对不可切除肝细胞癌门静脉癌栓患者放射治疗效果的评价[J/OL]. 中华医学超声杂志(电子版), 2024, 21(08): 778-784.
[3] 严华悦, 刘子祥, 周少波. 磷酸烯醇式丙酮酸羧激酶-1在恶性肿瘤中的研究进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 452-456.
[4] 高俊颖, 张海洲, 区泓乐, 孙强. FOLFOX-HAIC 为基础的肝细胞癌辅助转化治疗的应用进展[J/OL]. 中华普通外科学文献(电子版), 2024, 18(06): 457-463.
[5] 李华志, 曹广, 刘殿刚, 张雅静. 不同入路下行肝切除术治疗原发性肝细胞癌的临床对比[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 52-55.
[6] 陈浩, 王萌. 胃印戒细胞癌的临床病理特征及治疗选择的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 108-111.
[7] 刘柏隆, 周祥福. 压力性尿失禁阶梯治疗的项目介绍[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 125-125.
[8] 刘柏隆. 女性压力性尿失禁阶梯治疗之手术治疗方案选择[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2025, 19(01): 126-126.
[9] 刘琦, 王守凯, 王帅, 苏雨晴, 马壮, 陈海军, 司丕蕾. 乳腺癌肿瘤内微生物组的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 841-845.
[10] 李浩, 陈棋帅, 费发珠, 张宁伟, 李元东, 王硕晨, 任宾. 慢性肝病肝纤维化无创诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 863-867.
[11] 谭瑞义. 小细胞骨肉瘤诊断及治疗研究现状与进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(08): 781-784.
[12] 崔军威, 蔡华丽, 胡艺冰, 胡慧. 亚甲蓝联合金属定位夹及定位钩针标记在乳腺癌辅助化疗后评估腋窝转移淋巴结的临床应用价值探究[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 625-632.
[13] 王誉英, 刘世伟, 王睿, 曾娅玲, 涂禧慧, 张蒲蓉. 老年乳腺癌新辅助治疗病理完全缓解的预测因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 641-646.
[14] 王子阳, 王宏宾, 刘晓旌. 血清标志物对甲胎蛋白阴性肝细胞癌诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 677-681.
[15] 陈慧, 邹祖鹏, 周田田, 张艺丹, 张海萍. 皮肤镜对头皮红斑性皮肤病辅助鉴别诊断的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 692-698.
阅读次数
全文


摘要


AI


AI小编
你好!我是《中华医学电子期刊资源库》AI小编,有什么可以帮您的吗?